(BD-211)-在研适应症：地中海贫血_专利_临床

概要

基本信息

药物类型

造血干细胞疗法、基因疗法

别名

BD-211、BD 211

靶点-

作用机制

细胞替代物

治疗领域

遗传病与畸形、血液及淋巴系统疾病

在研适应症

地中海贫血

非在研适应症-

原研机构

上海本导基因技术有限公司

在研机构

上海本导基因技术有限公司

非在研机构-

最高研发状态(全球)临床阶段不明

首次获批日期(全球)-

最高研发状态(中国)临床阶段不明

特殊审评-

关联

3

项与 BD-211 相关的临床试验

NCT05776173 / Not yet recruitingN/A

Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemia

This study will be intented to evaluate the safety and efficacy of lentiviral vector transduction of β-globin genetically modified autologous CD34+ hematopoietic stem cells in patients with transfusion-dependent β-thalassemia.

开始日期2023-03-01

申办/合作机构

上海本导基因技术有限公司

[+1]

NCT05773729 / Not yet recruitingN/A

Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemia

This study will be intented to evaluate the safety and efficacy of lentiviral vector transduction of β-globin genetically modified autologous CD34+ hematopoietic stem cells in patients with transfusion-dependent β-thalassemia.

开始日期2023-03-01

申办/合作机构

上海本导基因技术有限公司

[+1]

NCT05015920 / RecruitingN/A

A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-Globin

This is a Phase 1,open label,safety,and efficacy study in subjects with non-β0/β0 TDT β-thalassemia Major by transplanting BD211 drug product which is for autologous use only,via a single IV administration.

开始日期2021-04-01

申办/合作机构

上海本导基因技术有限公司

[+1]

100 项与 BD-211 相关的专利（医药）

登录后查看更多信息